|
“Innovative World” Scientific Research Support Center www.inno-world.uzBog'liq 3. Yakubova,Dusmurodova 1-kitob, 1- ДИУМ bildirish1111 - копия, KTE 6-top 12-var, 12-amaliy mashg\'ulot“Innovative World” Scientific Research Support Center www.inno-world.uz
D4: bias due to deviations from intended interventions
D5: bias due to missing data
D6: bias in measurement of outcomes
D7: bias in selection of the reported result
Results of individual studies
Study 1
The group receiving tests (honey plus oral ACV) demonstrated a significantly
earlier disappearance of herpetic oral lesions compared to controls (oral ACV)
with a median of 3 days versus 6 days (p = 0.022). Additionally, notable
improvements were observed in drooling (2 days vs. 4 days, p = 0.030) and eating
difficulty (3 days vs. 8 days, p = 0.001). The test group also exhibited significant
enhancements in the severity of oral lesions, lower pain scores, improved eating
and drinking ability, and a notably reduced need for analgesics at three
assessment time-points. Although fever disappeared in both groups, there was no
statistically significant difference [16].
Study 2
Children who received acyclovir (ACV) experienced a shorter duration of oral
lesions compared to those receiving a placebo, with a median of 4 days versus 10
days (difference of 6 days, 95% confidence interval 4.0 to 8.0). Additionally, the
ACV group exhibited an earlier resolution of various signs and symptoms,
including fever (1 vs. 3 days, 2 days, 0.8 to 3.2), extraoral lesions (0 vs. 5.5 days,
5.5 days, 1.3 to 4.7), eating difficulties (4 vs. 7 days, 3 days, 1.31 to 4.69), and
drinking difficulties (3 vs. 6 days, 3 days, 1.1 to 4.9). Moreover, viral shedding was
significantly shorter in the acyclovir-treated group, lasting 1 day compared to 5
days in the placebo group (4 days, 2.9 to 5.1) [17].
Study 3
Topical therapy involving maalox and diphenhydramine or viscous lidocaine
was administered to 73% and 15% of the patients, respectively, while acyclovir
(ACV) was only administered to 17% of the cases. The dosing and administration
of topical agents for the treatment of primary herpetic gingivostomatitis (PHGS)
in preschoolers posed challenges, with ACV being underutilized compared to
other topical treatments [18].
Study 4
In assessing the severity of oral lesions, all therapies demonstrated
effectiveness, except for mild lesions where no statistically significant
improvement was observed in any group (group A: non-alcoholic chlorhexidine
(CHX) rinses; group B: non-alcoholic chlorhexidine rinses plus hyaluronic acid
gel; group C: non-alcoholic chlorhexidine rinses plus Mucosyte®). For moderate
lesions, group C exhibited a significantly larger number of patients with complete
healing or improvement compared to group A. No difference was recorded for
mild/severe lesions.
Regarding pain scores, a statistically significant difference was observed from
T0 to T1 for all groups. Group C showed a significant decrease in pain scores
compared to group A.
In terms of eating and drinking ability, all patients experienced either total or
|
| |
